Table 2:

Geometric mean (GM) serum concentrations and 95% Confidence Intervals (CI) of pregnenolone, progesterone, and related metabolites (pmol/l) among postmenopausal endometrial and ovarian cancer cases and subcohort members, a case-cohort study within B~FIT.

	Endometrial Cancer
	Cases (n=65)		Subcohort (n=345)		P value
Hormone measures (pmol/l)	GM	95% CI	GM	95% CI
Pregnenolone	417.18	(373.04–466.54)	463.83	(441.86–486.89)	0.09
17 OH-Pregnenolone	2263.17	(2,059.05–2,487.53)	2594.89	(2,490.60–2,703.55)	0.01
Progesterone	140.40	(129.93–151.71)	138.75	(134.16–143.49)	0.78
17 OH-Progesterone	391.90	(350.30–438.44)	402.75	(383.60–422.84)	0.66
5αP	202.91	(179.28–229.65)	220.04	(208.53–232.19)	0.24
3αHP	57.47	(50.03–66.02)	62.19	(58.56–66.04)	0.31
20αHP	162.37	(150.11–175.64)	147.08	(142.15–152.18)	0.02
Estradiol	75.20	(65.50–84.89)	47.96	(43.75–52.17)	<0.0001
Progesterone:estradiol ratio*	2.38	(2.00–2.82)	3.57	(3.32–3.85)	<0.0001
	Ovarian Cancer
	Cases (n=67)		Subcohort (n=413)		P value
	GM	95% CI	GM	95% CI
Pregnenolone	457.04	(409.30–510.34)	462.78	(442.78–483.67)	0.84
17 OH-Pregnenolone	2917.50	(2,655.90–3,204.86)	2612.65	(2,516.20–2,712.80)	0.03
Progesterone	146.33	(136.58–156.77)	139.84	(136.04–143.76)	0.23
17 OH-Progesterone	407.23	(364.40–455.11)	403.12	(385.57–421.47)	0.87
5αP	232.76	(207.99–260.48)	218.51	(208.88–228.58)	0.31
3αHP	68.88	(60.04–79.02)	64.10	(60.67–67.72)	0.34
20αHP	151.17	(140.35–162.83)	148.51	(144.16–152.99)	0.66
Estradiol	55.06	(42.09–68.04)	50.03	(44.81–55.24)	0.48
Progesterone:estradiol ratio*	3.48	(2.93–4.13)	3.55	(3.31–3.80)	0.83

^*Ratio calculated as pmol/L progesterone divided by pmol/L estradiol.